-+ 0.00%
-+ 0.00%
-+ 0.00%

TRAWS PHARMA REPORTS FINAL PHASE 2A RESULTS FOR RATUTRELVIR IN COVID-INFECTED SUBJECTS, SHOWING FEWER TREATMENT-RELATED ADVERSE EVENTS AND NO VIRAL REBOUNDS VERSUS PAXLOVID®

Reuters·11/12/2026 12:04:57